注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
RAPT Therapeutics Inc是一家临床阶段的基于免疫学的生物制药公司。该公司专注于为炎症性疾病和肿瘤学需求未得到满足的患者发现、开发和商业化口服小分子疗法。该公司利用其药物发现和开发引擎开发选择性小分子,旨在调节这些疾病背后的关键免疫反应。它的两种主要候选药物均针对C-C基序趋化因子受体4 (CCR4)。其炎症候选药物RPT193旨在选择性抑制2型T辅助细胞(Th2细胞)迁移到发炎组织中。其主要的肿瘤候选药物FLX475旨在选择性地抑制免疫抑制性调节性T细胞 (Treg) 迁移到肿瘤中。此外,RPT193在特应性皮炎(AD)以外的多种炎症性疾病中具有临床可转化性,包括过敏性哮喘和慢性鼻窦炎。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Brian Russell Wong | 49 | 2015 | CEO, President & Director |
Linda Kozick | 64 | 2016 | Independent Director |
William J. Rieflin | 61 | 2015 | Independent Chairman of the Board |
Michael F. Giordano | 63 | 2018 | Independent Director |
Alexander Rudensky | - | - | Chairman of Scientific Advisory Board |
David V. Goeddel | 69 | 2015 | Member of Scientific Advisory Board |
Drew Mark Pardoll | - | 2017 | Member of Scientific Advisory Board |
Antoni Ribas | 54 | - | Member of Scientific Advisory Board |
Robert Zamboni | - | - | Member of Scientific Advisory Board |
Scott Joseph Antonia | - | 2017 | Member of Scientific Advisory Board |
Emma Guttman-Yassky | - | 2019 | Member of Scientific Advisory Board |
Philip D. Greenberg | - | 2017 | Member of Scientific Advisory Board |
Wendye Robbins | 60 | 2019 | Independent Director |
Mary Ann Gray | 69 | 2019 | Independent Director |
Lori M. Lyons-Williams | 46 | 2021 | Independent Director |
Lawrence Fong | - | 2020 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核